Xing Q, Cheng W, Wang W, Jin C, Wang H
Front Pharmacol. 2025; 16:1474856.
PMID: 39911851
PMC: 11794068.
DOI: 10.3389/fphar.2025.1474856.
Kwon Y, Roberts E, Degenholtz H, Jacobs B, Sabik L
J Cancer Surviv. 2024; .
PMID: 38520599
PMC: 11417130.
DOI: 10.1007/s11764-024-01562-x.
Ramagopalan S, Diaz J, Mitchell G, Garrison Jr L, Kolchinsky P
BMC Med. 2024; 22(1):45.
PMID: 38287326
PMC: 10826180.
DOI: 10.1186/s12916-024-03262-w.
Odouard I, Anderson G, Alexander G, Ballreich J
J Manag Care Spec Pharm. 2023; 30(3):269-278.
PMID: 38140901
PMC: 10909581.
DOI: 10.18553/jmcp.2023.23153.
Lieneck C, McLauchlan M, Adachi V, Billings R
Pharmacy (Basel). 2023; 11(6).
PMID: 38133462
PMC: 10748351.
DOI: 10.3390/pharmacy11060187.
Access in all areas? A round up of developments in market access and health technology assessment: part 2.
Beattie A, Treharne C, Mardiguian S, Ramagopalan S
J Comp Eff Res. 2023; 12(12):e230162.
PMID: 37916681
PMC: 10734314.
DOI: 10.57264/cer-2023-0162.
The cancer premium - explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland: a cross sectional study.
Serra-Burriel M, Perenyi G, Laube Y, Mitchell A, Vokinger K
EClinicalMedicine. 2023; 61:102087.
PMID: 37521033
PMC: 10371812.
DOI: 10.1016/j.eclinm.2023.102087.
Medication Cost Concerns and Disparities in Patient-Reported Outcomes Among a Multiethnic Cohort of Patients With Systemic Lupus Erythematosus.
Aguirre A, DeQuattro K, Shiboski S, Katz P, Greenlund K, Barbour K
J Rheumatol. 2023; 50(10):1302-1309.
PMID: 37321640
PMC: 10543599.
DOI: 10.3899/jrheum.2023-0060.
Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy.
Chen Y, Dong H, Wei Y, Yang Y, Ming J, Yu H
BMJ. 2023; 381:e069963.
PMID: 37321628
PMC: 10266439.
DOI: 10.1136/bmj-2022-069963.
Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease.
Luo J, Feldman R, Callaway Kim K, Rothenberger S, Korytkowski M, Hernandez I
JAMA Netw Open. 2023; 6(6):e2317886.
PMID: 37307000
PMC: 10261995.
DOI: 10.1001/jamanetworkopen.2023.17886.
Pharmaceutical Purchasing: a Review of the Landscape and Implications for Antidotal Therapies.
Troger A, Burns M
J Med Toxicol. 2023; 19(3):262-267.
PMID: 37249803
PMC: 10293135.
DOI: 10.1007/s13181-023-00943-5.
The Next Generation of Payment Reforms for Population Health - An Actionable Agenda for 2035 Informed by Past Gains and Ongoing Lessons.
Kadakia K, Offodile 2nd A
Milbank Q. 2023; 101(S1):866-892.
PMID: 37096610
PMC: 10126963.
DOI: 10.1111/1468-0009.12632.
Drugs likely subject to Medicare negotiation, 2026-2028.
Dickson S, Hernandez I
J Manag Care Spec Pharm. 2023; 29(3):229-235.
PMID: 36840960
PMC: 10387900.
DOI: 10.18553/jmcp.2023.29.3.229.
Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
Rome B, Nagar S, Egilman A, Wang J, Feldman W, Kesselheim A
JAMA Health Forum. 2023; 4(1):e225218.
PMID: 36705916
PMC: 11901806.
DOI: 10.1001/jamahealthforum.2022.5218.
